Raymond James analyst Brian Peterson raised the firm’s price target on Veeva (VEEV) to $340 from $310 and keeps an Outperform rating on the shares. The company’s fiscal Q2 results brought progress on a number of key initiatives, including large top 20 pharma wins, the analyst tells investors in a research note. The firm has confidence in Veeva’s back half of 2025 revenue and billings trajectory.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: